NEVVI Medicare utilization intelligence
or

← back

Provider profile

ALHAJ MOUSTAFA, MUHAMAD M.D.

Hematology-Oncology · NPI 1023403201 · JACKSONVILLE, FL

1
Groups
55
Codes · 2024
70,908
Disclosed services

ALHAJ MOUSTAFA, MUHAMAD is a Hematology-Oncology in JACKSONVILLE, FL, a member of 1 medical group, who billed 55 distinct codes to Medicare Part B in 2024.

Groups: MAYO CLINIC JACKSONVILLE (JACKSONVILLE, FL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒

Provider overview · all codes · CY2024

70,908
disclosed services
55
codes billed to Medicare Part B
Prior year · CY2023 83,601 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J1453 Injection, fosaprepitant, 1 mg
J9299 Injection, nivolumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9263 Injection, oxaliplatin, 0.5 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J9075 Injection, cyclophosphamide, not otherwise specified, 5 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
J0461 Injection, atropine sulfate, 0.01 mg
Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J9041 Injection, bortezomib, 0.1 mg
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
J9206 Injection, irinotecan, 20 mg
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
J9045 Injection, carboplatin, 50 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J3480 Injection, potassium chloride, per 2 meq
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
36591 Collection of blood sample from implanted device
Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
J3475 Injection, magnesium sulfate, per 500 mg
J9190 Injection, fluorouracil, 500 mg
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J7030 Infusion, normal saline solution , 1000 cc
96372 Injection of drug or substance under skin or into muscle
96361 Infusion into a vein for hydration, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
J9060 Injection, cisplatin, powder or solution, 10 mg
J1200 Injection, diphenhydramine hcl, up to 50 mg
G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96360 Infusion into a vein for hydration, 31-60 minutes
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96411 Administration of additional new drug or substance into vein using push technique
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96374 Injection of drug or substance into vein
99239 Hospital discharge day management, more than 30 minutes
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.